German Spondyloarthritis Inception Cohort
Launched by CHARITE UNIVERSITY, BERLIN, GERMANY · Jan 14, 2011
Trial Information
Current as of June 28, 2025
Recruiting
Keywords
ClinConnect Summary
The German Spondyloarthritis Inception Cohort (GESPIC) is a long-term study that started in 2000, focusing on understanding early stages of spondyloarthritis (SpA), which includes conditions like ankylosing spondylitis and axial psoriatic arthritis. The researchers aim to learn how these diseases progress over time, what factors might influence their outcomes, and how they affect patients' quality of life and costs related to treatment. Recently, the study has expanded to include patients with related conditions such as Crohn's disease and acute anterior uveitis.
To participate in this study, individuals must have a confirmed diagnosis of axial spondyloarthritis, juvenile spondyloarthritis, Crohn's disease, acute anterior uveitis, or psoriatic arthritis with axial involvement. Participants can expect regular check-ups and assessments over several years, which will help researchers gather important information about these conditions. This study is currently recruiting patients of all ages and genders, making it a valuable opportunity for those affected by these diseases to contribute to important medical research.
Gender
ALL
Eligibility criteria
- Main inclusion Criteria:
- • Patients with definite diagnosis of axial spondyloarthritis or juvenile spondyloarthritis.
- • Patients with definite diagnosis of Crohn's disease.
- • Patients with definite diagnosis of acute anterior uveitis.
- • Patients with definite diagnosis of psoriatic arthritis with axial involvement.
About Charite University, Berlin, Germany
Charité - Universitätsmedizin Berlin is a leading academic medical center in Germany, renowned for its commitment to excellence in research, education, and patient care. As one of Europe's largest university hospitals, Charité integrates cutting-edge clinical practices with innovative research initiatives, fostering interdisciplinary collaboration across various medical fields. The institution is dedicated to advancing healthcare through rigorous clinical trials, contributing to the development of new therapies and treatment protocols. With a strong emphasis on translational medicine, Charité aims to bridge the gap between scientific discovery and practical application, ultimately enhancing patient outcomes and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Berlin, , Germany
Patients applied
Trial Officials
Joachim Sieper, Prof. Dr.
Study Chair
Charite University, Berlin, Germany
Martin Rudwaleit, Prof. Dr.
Study Chair
Charite University, Berlin, Germany
Denis Poddubnyy, Prof. Dr.
Study Chair
Charite University, Berlin, Germany
Fabian Proft, MD
Study Chair
Charite University, Berlin, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials